144 related articles for article (PubMed ID: 7964811)
21. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
22. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
[TBL] [Abstract][Full Text] [Related]
23. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Henney HR; Runyan JD
Int J Clin Pract; 2008 Feb; 62(2):314-24. PubMed ID: 18199279
[TBL] [Abstract][Full Text] [Related]
24. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
[TBL] [Abstract][Full Text] [Related]
25. Effect of antispastic drugs on motor reflexes and voluntary muscle contraction in incomplete spinal cord injury.
Chu VW; Hornby TG; Schmit BD
Arch Phys Med Rehabil; 2014 Apr; 95(4):622-32. PubMed ID: 24269485
[TBL] [Abstract][Full Text] [Related]
26. [Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke].
Gekht AB; Burd GS; Selikhova MV; Iaish F; Beliakov VV
Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(10):22-9. PubMed ID: 9819884
[TBL] [Abstract][Full Text] [Related]
27. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine.
Al-Ghazawi M; Alzoubi M; Faidi B
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):255-62. PubMed ID: 23380428
[TBL] [Abstract][Full Text] [Related]
29. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
30. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
31. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF
Zhang W; McIntyre C; Riehl T; Forbes H; Bertran E; Choi HJ; Lee DH; Lee J
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):651-658. PubMed ID: 32311241
[TBL] [Abstract][Full Text] [Related]
32. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
Shellenberger MK; Groves L; Shah J; Novack GD
Drug Metab Dispos; 1999 Feb; 27(2):201-4. PubMed ID: 9929503
[TBL] [Abstract][Full Text] [Related]
33. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
Smith HS; Barton AE
Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
[TBL] [Abstract][Full Text] [Related]
34. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
Weynants L; Van Laere M
Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
[No Abstract] [Full Text] [Related]
35. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.
Simpson DM; Gracies JM; Yablon SA; Barbano R; Brashear A;
J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):380-5. PubMed ID: 18977811
[TBL] [Abstract][Full Text] [Related]
36. Tizanidine--initial pharmacokinetic studies in patients with spasticity.
Heazlewood V; Symoniw P; Maruff P; Eadie MJ
Eur J Clin Pharmacol; 1983; 25(1):65-7. PubMed ID: 6617726
[TBL] [Abstract][Full Text] [Related]
37. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Hassan N; McLellan DL
J Neurol Neurosurg Psychiatry; 1980 Dec; 43(12):1132-6. PubMed ID: 7217960
[TBL] [Abstract][Full Text] [Related]
38. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
Wallace JD
Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats.
Skoog B
Acta Physiol Scand; 1996 Jan; 156(1):81-90. PubMed ID: 8866890
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of tizanidine action on spasticity.
Milanov I; Georgiev D
Acta Neurol Scand; 1994 Apr; 89(4):274-9. PubMed ID: 8042446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
